The global chemotherapies induced neutropenia treatment market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing incidence of cancer and rise in awareness about cancer treatments. The major players in this market are Novartis AG, Bayer AG, Pfizer Inc, Sanofi SA, and AstraZeneca plc.
Some Of The Growth Factors Of This Market:
- Chemotherapy-induced neutropenia is a condition that occurs when the chemotherapy drugs kill off too many of the body's white blood cells, which are needed to fight infection.
- Chemotherapy-induced neutropenia can be treated with antibiotics and other medications to help prevent infections.
- Chemotherapy-induced neutropenia is more common in people who have had previous chemotherapy treatments or who have a weakened immune system due to HIV/AIDS, cancer, or other conditions.
- The incidence of chemotherapy-induced neutropenia has been increasing over time as more people are being treated with chemotherapeutic agents for cancer and other diseases that cause immunosuppression.
Industry Growth Insights published a new data on “ChemOthersapy-Induced Neutropenia Treatment Market”. The research report is titled “ChemOthersapy-Induced Neutropenia Treatment Market research by Types (Antibiotic Therapy, Colony-Stimulating Factor Therapy, Granulocyte Transfusion, Splenectomy Procedure, Others), By Applications (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Players/Companies Amgen, Sanofi, Novartis AG, Baxter International, Teva Pharmaceuticals Industries, Apotex, Dr. Reddy’s Laboratory, Biogenomics Limited, Ligand Pharmaceuticals”.
Scope Of The Report
Report Attributes
Report Details
Report Title
ChemOthersapy-Induced Neutropenia Treatment Market Research Report
By Type
Antibiotic Therapy, Colony-Stimulating Factor Therapy, Granulocyte Transfusion, Splenectomy Procedure, Others
By Application
Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
By Companies
Amgen, Sanofi, Novartis AG, Baxter International, Teva Pharmaceuticals Industries, Apotex, Dr. Reddy’s Laboratory, Biogenomics Limited, Ligand Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global ChemOthersapy-Induced Neutropenia Treatment Market Report Segments:
The global ChemOthersapy-Induced Neutropenia Treatment market is segmented on the basis of:
Types
Antibiotic Therapy, Colony-Stimulating Factor Therapy, Granulocyte Transfusion, Splenectomy Procedure, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen
- Sanofi
- Novartis AG
- Baxter International
- Teva Pharmaceuticals Industries
- Apotex
- Dr. Reddy’s Laboratory
- Biogenomics Limited
- Ligand Pharmaceuticals
Highlights of The ChemOthersapy-Induced Neutropenia Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antibiotic Therapy
- Colony-Stimulating Factor Therapy
- Granulocyte Transfusion
- Splenectomy Procedure
- Others
- By Application:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the ChemOthersapy-Induced Neutropenia Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Chemotherapeutic-induced neutropenia (CIN) is a condition that can develop as a result of treatment with certain cancer drugs. CIN occurs when the body's immune system becomes weakened and is unable to fight off infections. This can lead to an increased risk of serious health problems, including pneumonia, sepsis, and even death.nnThere are several ways that chemotherapeutic agents can cause CIN. The most common way is through damage to the white blood cells (leukocytes) in the blood stream. Other causes include use of radiation therapy or chemotherapy treatments that target bone marrow cells or stem cells. Chemotherapy may also cause CIN if it is given in combination with other medications or treatments that weaken the immune system.
Some of the major companies in the chemothersapy-induced neutropenia treatment market are Amgen, Sanofi, Novartis AG, Baxter International, Teva Pharmaceuticals Industries, Apotex, Dr. Reddy¢â‚¬â„¢s Laboratory, Biogenomics Limited, Ligand Pharmaceuticals.
The chemothersapy-induced neutropenia treatment market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. ChemOthersapy-Induced Neutropenia Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. ChemOthersapy-Induced Neutropenia Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. ChemOthersapy-Induced Neutropenia Treatment Market - Supply Chain
4.5. Global ChemOthersapy-Induced Neutropenia Treatment Market Forecast
4.5.1. ChemOthersapy-Induced Neutropenia Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. ChemOthersapy-Induced Neutropenia Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. ChemOthersapy-Induced Neutropenia Treatment Market Absolute $ Opportunity
5. Global ChemOthersapy-Induced Neutropenia Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. ChemOthersapy-Induced Neutropenia Treatment Market Size and Volume Forecast by Type
5.3.1. Antibiotic Therapy
5.3.2. Colony-Stimulating Factor Therapy
5.3.3. Granulocyte Transfusion
5.3.4. Splenectomy Procedure
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global ChemOthersapy-Induced Neutropenia Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. ChemOthersapy-Induced Neutropenia Treatment Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacy
6.3.2. Retail Pharmacy
6.3.3. Online Pharmacy
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global ChemOthersapy-Induced Neutropenia Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. ChemOthersapy-Induced Neutropenia Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global ChemOthersapy-Induced Neutropenia Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. ChemOthersapy-Induced Neutropenia Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global ChemOthersapy-Induced Neutropenia Treatment Demand Share Forecast, 2019-2026
9. North America ChemOthersapy-Induced Neutropenia Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America ChemOthersapy-Induced Neutropenia Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America ChemOthersapy-Induced Neutropenia Treatment Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacy
9.4.2. Retail Pharmacy
9.4.3. Online Pharmacy
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America ChemOthersapy-Induced Neutropenia Treatment Market Size and Volume Forecast by Type
9.7.1. Antibiotic Therapy
9.7.2. Colony-Stimulating Factor Therapy
9.7.3. Granulocyte Transfusion
9.7.4. Splenectomy Procedure
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America ChemOthersapy-Induced Neutropenia Treatment Demand Share Forecast, 2019-2026
10. Latin America ChemOthersapy-Induced Neutropenia Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America ChemOthersapy-Induced Neutropenia Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America ChemOthersapy-Induced Neutropenia Treatment Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacy
10.4.2. Retail Pharmacy
10.4.3. Online Pharmacy
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America ChemOthersapy-Induced Neutropenia Treatment Market Size and Volume Forecast by Type
10.7.1. Antibiotic Therapy
10.7.2. Colony-Stimulating Factor Therapy
10.7.3. Granulocyte Transfusion
10.7.4. Splenectomy Procedure
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America ChemOthersapy-Induced Neutropenia Treatment Demand Share Forecast, 2019-2026
11. Europe ChemOthersapy-Induced Neutropenia Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe ChemOthersapy-Induced Neutropenia Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe ChemOthersapy-Induced Neutropenia Treatment Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacy
11.4.2. Retail Pharmacy
11.4.3. Online Pharmacy
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe ChemOthersapy-Induced Neutropenia Treatment Market Size and Volume Forecast by Type
11.7.1. Antibiotic Therapy
11.7.2. Colony-Stimulating Factor Therapy
11.7.3. Granulocyte Transfusion
11.7.4. Splenectomy Procedure
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe ChemOthersapy-Induced Neutropenia Treatment Demand Share, 2019-2026
12. Asia Pacific ChemOthersapy-Induced Neutropenia Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific ChemOthersapy-Induced Neutropenia Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific ChemOthersapy-Induced Neutropenia Treatment Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacy
12.4.2. Retail Pharmacy
12.4.3. Online Pharmacy
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific ChemOthersapy-Induced Neutropenia Treatment Market Size and Volume Forecast by Type
12.7.1. Antibiotic Therapy
12.7.2. Colony-Stimulating Factor Therapy
12.7.3. Granulocyte Transfusion
12.7.4. Splenectomy Procedure
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific ChemOthersapy-Induced Neutropenia Treatment Demand Share, 2019-2026
13. Middle East & Africa ChemOthersapy-Induced Neutropenia Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa ChemOthersapy-Induced Neutropenia Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa ChemOthersapy-Induced Neutropenia Treatment Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacy
13.4.2. Retail Pharmacy
13.4.3. Online Pharmacy
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa ChemOthersapy-Induced Neutropenia Treatment Market Size and Volume Forecast by Type
13.7.1. Antibiotic Therapy
13.7.2. Colony-Stimulating Factor Therapy
13.7.3. Granulocyte Transfusion
13.7.4. Splenectomy Procedure
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa ChemOthersapy-Induced Neutropenia Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global ChemOthersapy-Induced Neutropenia Treatment Market: Market Share Analysis
14.2. ChemOthersapy-Induced Neutropenia Treatment Distributors and Customers
14.3. ChemOthersapy-Induced Neutropenia Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Amgen
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Sanofi
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Novartis AG
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Baxter International
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Teva Pharmaceuticals Industries
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Apotex
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Dr. Reddys Laboratory
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Biogenomics Limited
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Ligand Pharmaceuticals
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
